Oncogenic/tumor-suppressor miR among ESCC.
Abstract
Noncoding RNA (ncRNA) includes short (miRNA) and long (lncRNA) that have important regulatory role in different biological processes. One of the important issue in which ncRNA involved is tumor induction and suppression. miRNA and lncRNA were vital players in many tumors including digestive system tumors. This study includes studying the role of 140 hsa-miR including miR-1 to miR-140 and their sponger lncRNA in esophageal and stomach cancers by 249 studies. The review revealed that each miR may play as oncogene only or tumor suppressor via upregulation and downregulation regulatory proteins in cell cycles and activation of physiological cascades. Some of miR have dual role in same type of tumor as oncogene and suppressive miR. Same thing is for lncRNA tacting as oncogenic via sponging some of miR when overexpressed to upregulate oncogenic protein or acting as suppression lncRNA when overexpressed to downregulate some oncogenic proteins activated by miR. The current review concludes the vital role of ncRNA (both miRNA and lncRNA) in some digestive system tumors as oncogene-promoting cancer viability, invasiveness, proliferation, and metastasis or as tumor suppressor inhibiting tumorigenicity or inducing apoptosis.
Keywords
- miRNA
- lncRNA
- sponge
- oncogene
- tumor suppressor
- esophageal tumors
- gastric cancers
1. Introduction
Ribonucleic acids (RNAs) are important nucleic acids for cell life and are classified as coding and non-coding RNA (ncRNAs). MicroRNAs (miRNAs) are a class of short noncoding RNAs (ncRNAs) (22 nts) that play important roles in posttranscriptional gene regulation. The majority of miRNAs are transcribed from DNA sequences into primary miRNAs and processed into precursor miRNAs, and finally mature miRNAs [1]. Long noncoding RNAs (lncRNAs) (more than 200 nts) may regulate cell proliferation, apoptosis, migration, invasion, and maintenance of stemness during cancer development [2, 3]. miRNA has a role in many tumors and upregulation/downregulation status of them may influence tumorigenesis, proliferation, metastasis, and chemoresistance [4, 5]. miRNAs implicated as oncogene of repressors for sets of cancers of liver: focal nodular hyperplasia (FNH) [6], hepatocellular adenoma (HCA) [7], hepatocellular carcinoma (HCC) [8], and cholangiocarcinomas (CCA) [9]. miRNAs were also implicated in pancreatic cancers: pancreatic endocrine tumors (PET) [10], pancreatic ductal adenocarcinoma (PDAC), and pancreatic acinar cell carcinoma (PACC) [11]. Esophageal squamous-cell carcinoma (ESCC) [12], and esophageal adenocarcinoma (EAC) [13], stomach adenocarcinoma (STAD) [14], colon adenocarcinoma (COAD) [15] were also influenced by miRNAs. The current review focused on 140 types of miR (miR-1 to miR-140) as oncogenic or tumor suppressor miR in different digestive system tumors.
1.1 Esophageal cancers
Esophageal cancer is a disease in which malignant (cancer) cells form in the tissues of the esophagus. It is characterized by its high mortality rate and poor prognosis. This disease is the sixth cause of cancer-related deaths and the eighth most common cancer worldwide with a 5-year survival rate of less than 25% [15]. Esophageal cancer occurs as either squamous cell carcinomas (ESCC) or adenocarcinoma (EAC). ncRNA including miRNA and lncRNA has a vital role in esophageal cancers either as oncogenic or as tumor suppressor [16, 17].
1.1.1 lncRNA/miR interaction in esophageal squamous cell carcinoma (ESCC)
Esophageal squamous cell carcinoma (ESCC) is a cancer that forms in the thin, flat cells lining the inside of the esophagus. It accounts for about 90% of esophageal cancers. miRNA can play a vital role in cancer regulation and may be an oncogene or tumor suppressor gene when overexpressed. In esophageal squamous cell carcinoma (ESCC), miR-1, −22, −26, −27, −29, −30, −33, −34, −98, −99, −100, −101, −107, −122, −124, −125, −127, −128, −129, −133, −134, −136, −137, −138, −139, and − 140 were downregulated in ESCC tissues compared with normal one acting as tumor suppressor and targeting different genes [18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43]. In contrast, the expression of miR-7, −9, −10, −16, −17, −18, −19, −20, −21, −23, −24, −25, −28, −31, −32, −92, −93, −96, −103, −105, −106, −126, −130-, and miR-135 was upregulated in ESCC acting as oncogene [44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66], as shown in Table 1.
miRNA | Expression in ESCC | Role in ESCC | Target gene | Ref. |
---|---|---|---|---|
miR-1 | Downregulated | Tumor-suppressor | NOTCH2, LASP1 | [18] |
miR-22 | Downregulated | Tumor-suppressor | PTEN, C-MYC | [19] |
miR-26 | Downregulated | Tumor-suppressor | MYCBP | [20] |
miR-27 | Downregulated | Tumor-suppressor | FBXW7 | [21] |
miR-29 | Downregulated | Tumor-suppressor | FBXO31 | [22] |
miR-30 | Downregulated | Tumor-suppressor | ITGA5, PDGFRB | [23] |
miR-33 | Downregulated | Tumor-suppressor | ZEB1 | [24] |
miR-34 | Downregulated | Tumor-suppressor | c-MET, FOXM1 | [25] |
miR-98 | Downregulated | Tumor-suppressor | EZH2 | [26] |
miR-99 | Downregulated | Tumor-suppressor | CCND1, CCNA2 | [27] |
miR-100 | Downregulated | Tumor-suppressor | CXCR7 | [28] |
miR-101 | Downregulated | Tumor-suppressor | COX-2 | [29] |
miR-107 | Downregulated | Tumor-suppressor | CDC42 | [30] |
miR-122 | Downregulated | Tumor-suppressor | KIF22 | [31] |
miR-124 | Downregulated | Tumor-suppressor | BCAT1 | [32] |
miR-125 | Downregulated | Tumor-suppressor | p38-MAPK | [33] |
miR-127 | Downregulated | Tumor-suppressor | FMNL3 | [34] |
miR-128 | Downregulated | Tumor-suppressor | ZEB1 | [35] |
miR-129 | Downregulated | Tumor-suppressor | CTBP2 | [36] |
miR-133 | Downregulated | Tumor-suppressor | COL1A1 | [37] |
miR-134 | Downregulated | Tumor-suppressor | FOXM1 | [38] |
miR-136 | Downregulated | Tumor-suppressor | MUC1 | [39] |
miR-137 | Downregulated | Tumor-suppressor | EZH2, PXN | [40] |
miR-138 | Downregulated | Tumor-suppressor | NF-κB | [41] |
miR-139 | Downregulated | Tumor-suppressor | NR5A2 | [42] |
miR-140 | Downregulated | Tumor-suppressor | ZEB1 | [43] |
miR-7 | Downregulated | Tumor-suppressor | HOXB13 | [44] |
miR-9 | Overexpressed | Oncogene | E-cadherin, FOXO1 | [45] |
miR-10 | Overexpressed | Oncogene | FOXO3, KLF4 | [46] |
miR-16 | Overexpressed | Oncogene | RECK, SOX6 | [47] |
miR-17 | Overexpressed | Oncogene | RBL2 | [48] |
miR-18 | Overexpressed | Oncogene | KRAS | [49] |
miR-19 | Overexpressed | Oncogene | CDC42, RAC1 | [50] |
miR-20 | Overexpressed | Oncogene | RB1, TP53INP1 | [51] |
miR-21 | Overexpressed | Oncogene | TPM1, PTEN | [52] |
miR-23 | Overexpressed | Oncogene | EBF3 | [53] |
miR-24 | Overexpressed | Oncogene | FBXW7 | [54] |
miR-25 | Overexpressed | Oncogene | PTEN, ZNF512B | [55] |
miR-28 | Overexpressed | Oncogene | ARF6 | [56] |
miR-31 | Overexpressed | Oncogene | LATS2 | [57] |
miR-32 | Overexpressed | Oncogene | CXXC5 | [58] |
miR-92 | Overexpressed | Oncogene | PTEN | [59] |
miR-93 | Overexpressed | Oncogene | TGFβR2 | [60] |
miR-96 | Overexpressed | Oncogene | [61] | |
miR-103 | Overexpressed | Oncogene | CDH11, NR3C1 | [62] |
miR-105 | Overexpressed | Oncogene | SPARCL1, FAK | [63] |
miR-106 | Overexpressed | Oncogene | PTEN | [64] |
miR-126 | Overexpressed | Oncogene | STAT3 | [65] |
miR-135 | Overexpressed | Oncogene | RERG | [66] |
Actually, lncRNA may have oncogenic activity acting as molecular sponge to inhibit activity of tumor suppressor miR. lncRNA opposite in action with tumor suppressor miR will act as oncogenic lncRNA, as shown in Table 2. HOX transcript antisense RNA (HOTAIR) expression increased in ESCC and inhibit the activity of miR-1. HOTAIR can be used as diagnostic marker of ESCC. miR-1 exert its suppressive action on ESCC via gene suppression of hepatocyte-growth factor (CCND1, CDK4, and MET). HOTAIR-mediated sponging of miR-1 leads to upregulation of those growth factors leading to ESCC proliferation and propagation [67]. Zinc finger E-box binding homeobox 1 (ZEB1) is transcriptional factor responsible for metastasis in ESCC, which is dysregulated by miR-33 to improve the outcome of ESCC. Differentiation antagonizing nonprotein coding RNA (DANCR) is lncRNA, which downregulates miR-33 and upregulates ZEB1 and so participates in worseness of ESCC [68]. Another lncRNA called MIR31HG acts on miR-34 leading to upregulation of c-Met promoting ESCC [69]. SNHG16 is also lncRNA of miR-98 that directly binds to enhancer of zeste homolog 2 (EZH2) and promotes ESCC propagation [70]. ANRIL is lncRNA of miR-99, which also promotes ESCC proliferation
lncRNA | Expression of lncRNA in ESCC | Target miR | Target gene | Ref. |
---|---|---|---|---|
HOTAIR | Overexpressed | miR-1 | CCND1, CDK4, and MET | [67] |
DANCR | Overexpressed | miR-33 | ZEB1 | [68] |
MIR31HG | Overexpressed | miR-34 | c-Met | [69] |
SNHG16 | Overexpressed | miR-98 | EZH2 | [70] |
ANRIL | Overexpressed | miR-99 | — | [71] |
MALAT1 | Overexpressed | miR-101 | — | [72] |
FAM201A | Overexpressed | miR-101 | mTOR | [73] |
LINC00152 | Overexpressed | miR-107 | Rab10 | [74] |
LINC01296 | Overexpressed | miR-122 | mTOR | [75] |
ZFAS1 | Overexpressed | miR-124 | STAT3 | [76] |
HOTAIR | Overexpressed | miR-125 | HK2 | [77] |
NEAT1 | Overexpressed | miR-129 | CTBP2 | [36] |
H19 | Overexpressed | miR-138 | EZH2 | [78] |
BCAR4 | Overexpressed | miR-139 | ELAVL1 | [79] |
SNHG16 | Overexpressed | miR-140 | ZEB1 | [43] |
LincIN | Overexpressed | miR-7 | HOXB13 | [80] |
MEG3 | Downregulated | miR-9 | E-cadherin, FOXO1 | [81] |
FAM83H-AS1 | Overexpressed | miR-10 | — | [82] |
PART1 | Downregulated | miR-18 | SOX6 | [83] |
GAS5 | Downregulated | miR-21 | RECK | [84] |
AC012073.1 | Downregulated | miR-93 | — | [85] |
lncRNA can act as tumor suppressor counteracting the effect of oncogenic miR. Maternally expressed gene 3 (MEG3) is tumor suppressor lncRNA of miR-9. MEG3 decreased expression was seen in ESCC. Expression level of MEG3 was significantly increased in cancer cells after being treated with the DNA methyltransferase inhibitor 5-Aza-dC, leading to decreased miR-9 and increased E-cadherin and FOXO1 expression [81]. miR-10 can be sponged by lncRNA FAM83H-AS1 in ESCC [82]. Prostate androgen-regulated transcript 1 (PART1) lncRNA was downregulated in ESCC and, when overexpressed, will sponge oncogenic miR-18 leading to upregulation of SOX6 thereby inhibiting ESCC proliferation and metastasis [83]. Growth arrest-specific 5 (GAS5) lncRNA is seen to be elevated in radiation-sensitive ESCC tissues, leading to dysregulation of miR-21 and increasing the level of its target, RECK [84]. lncRNA called AC012073.1 is seen to bind competitively to miR-93 in ESCC [85] as shown in Table 2.
1.1.2 lncRNA/miR interaction in esophageal adenocarcinoma (EAC)
Esophageal adenocarcinoma (EAC) is a malignancy classically seen in the distal esophagus. The incidence of EAC is seven times more common in men than in women [86]. lncRNA and miRNA can either be oncogenic promoting tumor proliferation, invasion, and metastasis or acting as a tumor suppressor via targeting specific protein and signaling pathways. It seems few studies were conducted on miR role in tumorigenesis or anti-tumor in EAC, but many studies highlighted the pivotal role of lncRNA. lncRNA called miR205HG was found to have tumor suppressory effect on EAC when overexpressed
lncRNA | Expression of lncRNA in EAC | Target miR | Target gene | Ref. |
---|---|---|---|---|
miR205HG | Downregulated | NA | Hedgehog | [87] |
HOTAIR | Overexpressed | NA | NTRK2, NP1, CHRDL1, NTRK2, HOXC8 and IL11 | [88] |
CYP1B1-AS1 | Downregulated | NA | NA | [88] |
AFAP1-AS1 | Overexpressed | NA | NA | [89] |
HNF1A-AS1 | Overexpressed | NA | H19 | [90] |
PVT1 | Overexpressed | NA | LATS1, YAP1 | [91] |
MIR22HG | Overexpressed | NA | STAT3 | [92] |
BDNF-AS | Downregulated | miR-214 | JAG1 | [92] |
ADAMTS9- AS2 | Downregulated | NA | CDH3 | [93] |
LINC00662 | Overexpressed | NA | Wnt/β-catenin | [94] |
1.2 Stomach cancers
Gastric or stomach cancers were also regulated by miR/lncRNA interactions. miR-1 directly targets the MET gene and downregulates its expression acting as tumor suppressor [95]. MET is an oncogene and its activation results from the binding of hepatocyte growth factor (HGF), leading to tumor growth, metastasis, migration, and drug resistance [96]. Targeting MET by miR-1 will deactivate it, and MET can restore its activity by oncogenic lncRNA called LINC00242 when sponging the miR-1 [97]. miR-7 also acting as a tumor suppressor in gastric cancer may be
<>Oncogenic miR-21 can promote gastric cancer cell viability and progression via downregulation of some tumor suppressor genes like PTEN, RECK, and PDCD4 [107]. Inhibiting miR-21 expression by lncRNA MEG3 can inhibit gastric cancer growth and metastasis [108]. miR-22 acts to suppress gastric cancer via upregulating MMP14, NET1, and Snail while lncRNA CTC-497E21.4 can squeegee miR-22 and promote proliferation and invasion [109]. miR-24 and miR-25 were upregulated in gastric cancer tissues and may promote the occurrence, development, infiltration, and metastasis of gastric cancer. As oncogenic miR-24 inhibits the CDKN1B and CHEK1 and miR-25 targeting FOXO3 [110, 111]. Tumor suppressor lncRNA GATA6-AS acts to inhibit gastric cancer progression by sponging miR-25 [112]. Targeting PTEN, miR-26 acts as oncogenic and upregulated in gastric cancer tissues promoting proliferation and invasion. Additionally, miR-26 can target EZH2 and can be suppressed by tumor suppressor lncRNA TET1–3 [113, 114]. miR-27 is additional oncogenic miR acting on HOXA10 [115]. By inhibiting the phosphorylation of AKT protein in gastric cancer cells, miR-28 acts as inhibiting progression and metastasis and can be sponged by LOC400043 [116, 117]. Low expression was seen in gastric cancer tissues for miR-29 highlighting their role as tumor suppressor targeting CCND2 and MMP2, and can be sponged by lncRNA MEG3 [118, 119]. As tumor suppressor, miR-30 is responsible for inhibiting gastric cancer and increasing sensitivity to anticancer drugs when upregulated [120], and lncRNA PVT1, HNF1A-AS1, and DLEU2 can sponge miR-30 and upregulating Snail protein, PI3K/AKT signaling pathway and ETS2, respectively, promoting gastric cancer cell proliferation and metastasis [121, 122, 123].
Conversely, it can be acting as oncogenic miR through P53/ROS-mediated regulation of the mitochondrial apoptotic pathway [124]. miR-31 acts as a vital tumor suppressor ncRNA by inhibiting E2F2s and RhoA expression, also upregulation of miR-31 targeting ITGA5 may suppress tumor cell invasion and metastasis by indirectly regulating PI3K/AKT signaling pathway in human SGC7901 GC cells [125, 126]. lncRNA MIR31HG can encourage gastric cancer cell proliferation and invasion via sponging miR-31 [127]. Another oncogenic miR is miR-32, which augments tumorigenesis of gastric cell cancer by targeting KLF4 and KLF2, and at the same time can be sponged by SNHG5 lncRNA [128]. Gastric cancer suppresivity of miR-33 and miR-34 by targeting CDK6, CCND1, and PIM1 via miR-33 and Bcl-2, Notch, and HMGA2 via miR-34 [129, 130].
Overexpression of miR-43 was seen in gastric cancer tissues that promotes proliferation and metastasis by targeting VEZT [131]. miR-92 suppresses proliferation of gastric cancer and induces apoptosis by targeting EP4, Notch1 [132], and by targeting SOX4 while sponging of miR-92 by lncRNA PITPNA-AS1 and MT1JP can promote gastric cancer migration via upregulation of SOX4 and FBXW7 respectively [133, 134]. Oncogenic miR-93 can promote tumorigenesis by downregulation of IFNAR1 or PTEN [135, 136], and gastric cancer suppressor lncRNA PTENP1, GPC5-AS1, and CA3-AS1 can achieve gastric cancer inhibition by sponging miR93 and upregulating PTEN, GPC5, and PTG3 respectively [136, 137, 138]. Dual effect of miR-95 targeting EMP1 as oncogene or tumor suppressor by targeting Slug [139, 140]. Oncogenic miR-96 can target
Tumor suppressor miR-101 targeting: ANXA2 [155], ZEB1 [156], SOCS2 [157], PI3K/AKT/mTOR [158], EZH2 [159], and AMPK [160] and sponged by LINC01303 and lncRNA XIST by upregulating EZH2 [159, 161], lncRNA SPRY4-IT1 by upregulating AMPK [160], lncRNA SNHG6 by upregulating ZEB1 [162] and lncRNA LINC00943 [163]. Dual oncogenic and tumor suppressive effects of miR-103 were elucidated in gastric cancer. It was found that overexpressed caveolin-1 and RAB10 were targets for suppressive miR-103 [164, 165] while miR-103 acting as oncogenic by downregulation of KLF4 [166]. lncRNA LINC00152 acting as oncogenic by sponging miR-103 and upregulation of RAB10 [165]. miR-105 inhibits gastric cancer cell metastasis, by targeting SOX9 and YY1 [167, 168, 169]. miR-106 play an oncogenic role in gastric cancer [170]. lncRNA GPC5-AS1 acting as tumor suppressor for gastric cancer via sponging miR-106 and upregulation of GPC5 [137]. Like miR-103, miR-107 has onogenic and tumor suppressive effects in gastric cancers, oncogenic by downregulation of PTEN [171], NF1 [172], and HIF-1α [173] suppressive by targeting BDNF [174]. lncRNA ZFR and PCAT18 counteracting oncogenic effect of miR-107 by upregulation of PTEN [171, 175]. Suppresivity of miR-122 may be linked to their target downregulation including DUSP4 [176], LYN [177], MYC [178], MMP-9 [179], GIT-1 [180], and VEGFD [181] while their effect can be sponged by lncRNA LINC01296, CRART16, and promoting metastasis by upregulation of MMP-9 and VEGFD respectively [179, 181]. Same thing for miR-124, they inhibit gastric cancer by downregulating many oncogenes like SPHK1 [182], ROCK1 [183], RAC1 and SP1 [184], EZH2 [185, 186], DNMT3B [187], and ITGB3 [188]. lncRNA MALAT1, LINC00511, LINC00240, and HOXA11-AS were overexpressed in gastric cancer as oncogene promoting cancer cell viability, proliferation, and metastasis via sponging miR-124 and upregulating EZH2, DNMT3B and ITGB3 respectively [185, 186, 187, 188]. Tumor suppresivity of miR-125 on gastric cancers was attributed to downregulation of many proteins inhibiting proliferation and metastasis: MCL1, BRMS1, VEGF-A, and HER2 [189, 190, 191, 192], while lncRNA PVT1 was the only oncogenic ncRNA sponging miR-125 in gastric cancer [193]. Tumor suppressor miR-126 can inhibit proliferation and metastasis of gastric cancers by downregulation of CRKL, VEGF-A, CXCR4, ADAM9, BRCC3, and PIK3R2 [194, 195, 196, 197, 198, 199] while TMPO-AS1 and HOTAIR were two oncogenic lncRNA promoting invasion and metastasis by upregulation of BRCC3 and PIK3R2, and sponging miR-126 [198, 199]. As tumor suppressor acting to downregulate MAPK4, WNT7a, SORT1, and MTDH by miR-127 and inhibiting gastric cancer invasion [200, 201, 202, 203]. SORT1 and MTDH can be upregulated by sponging miR-127 by lncRNA circ_0110389 and circALPL respectively [202, 203]. Four lncRNA were found to be oncogenic and sponging the tumor suppressor miR-128 and upregulating their targets leading to promoting gastric cancer proliferation and metastasis: lncRNA CCL2 with PARP2, lncRNA HCP5 with HMGA2, lncRNA PCAT1 with ZEB1, and lncRNA LINC01091 with ELF4 [204, 205, 206, 207]. Additional 4 oncogenic lncRNA were upregulated in gastric cancer tissues and downregulated miR-129: GACAT2, GACAT3, AC130710, and PCGEM1, which upregulate P4HA2 [208, 209, 210]. Oncogenic miR-130 promotes gastric cancer invasion and metastasis by downregulation of TGFβR2, C-MYB, and GCNT4 [211, 212, 213] while lncRNA MRPL39 acts to suppress the metastasis by sponging miR-130 [214]. Tumor suppressor miR-132 inhibits gastric tumor invasiveness and metastasis via downregulation of MUC13, CD44 and fibronectin1 (FN1), KIF21B, and PXN [215, 216, 217, 218], while lncRNA XIST can sponge miR-132 and upregulate PXN [218]. miR-134 and their lncRNA can have dual effects as tumor suppressor or oncogene and vice versa. By targeting and downregulation of GOLPH3, YY1 and YWHAZ [219, 220, 221] miR-134 acting as gastric cancer suppressor while acting as oncogene to deactivate PTEN while lncRNA circPTK2 can sponge miR-134 to activate PTEN inhibiting proliferation and metastasis [222]. Inversely lncRNA LUCAT1 can act as oncogene sponging suppressor miR-134 and upregulation of YWHAZ [221]. Oncogenic miR-135 can downregulate E2F1 and DAPK2 [223] and upregulate WNT [224] while miR-135 can act as gastric cancer suppressor downregulating SMAD2 [225]. Gastric cancer metastasis and invasion can be promoted by sponging of miR-136 by lncRNA circ_0110389 and circ_100876 leading to upregulation of SORT1 and MIEN1 respectively [202, 226]. Sponging of miR-137 by lncRNA like DSCR8, NCK1-AS1, and circHECTD1 can promote invasion and proliferation of gastric cancer by upregulation of CDC42, NUP43, and PBX3 respectively [227, 228, 229]. miR-138 inhibits gastric cancer vitality and progression by downregulation of ITGA2, PLAU, FOXC1, and SIRT2, which can be upregulated after sponging miR-138 by lncRNA UBE2CP3, TRPM2-AS, MCM3AP-AS1, and LINC00152 respectively [230, 231, 232, 233]. Same miR-138, miR-139 is tumor suppressor ncRNA inhibiting of tumorgenicity and their effect can be sponged by lncRNA, which promote tumorigenicity via upregulation of MYB, MMP11, PRKAA1, ELK1, and SOX4 by lncRNA SNHG3, CTBP1-AS2, LINC00152, Circ-PTPDC1, and circ_0000218 respectively [234, 235, 236, 237, 238]. Tumor suppresivity of miR-140 in gastric cancer was achieved via decreasing the expression of ATG5, SOX4, ADAM10, and NDRG3. Inverse effect (oncogenic) on gastric cancer can be accomplished by lncRNA CCAT1, TMPO-AS1, SNHG1, and SNHG20, which upregulate previously mentioned proteins respectively [239, 240, 241, 242] (Tables 4 and 5).
miRNA | Expression in ESCC | Role in ESCC | Target gene | Ref. |
---|---|---|---|---|
miR-1 | Downregulated | Tumor-suppressor | MET | [95] |
miR-7 | Downregulated | Tumor-suppressor | EGFR | [243] |
miR-9 | Overexpressed | Oncogenic | CDX2 | [99] |
miR-9 | Downregulated | Tumor-suppressor | MYH9 | [100] |
miR-17 | Overexpressed | Oncogenic | PTEN, EGR2 | [101, 102] |
miR-18 | Overexpressed | Oncogenic | IRF2 | [104] |
miR-19 | Overexpressed | Oncogenic | NA | [106] |
miR-20 | Overexpressed | Oncogenic | NA | [106] |
miR-21 | Overexpressed | Oncogenic | PTEN, RECK, and PDCD4 | [107] |
miR-22 | Downregulated | Tumor-suppressor | MMP14, NET1, and Snail | [109] |
miR-24 | Overexpressed | Oncogenic | CDKN1B and CHEK1 | [110] |
miR-25 | Overexpressed | Oncogenic | FOXO3 | [111] |
miR-26 | Overexpressed | Oncogenic | PTEN, EZH2 | [113] |
miR-27 | Overexpressed | Oncogenic | HOXA10 | [115] |
miR-28 | Downregulated | Tumor-suppressor | AKT | [116] |
miR-29 | Downregulated | Tumor-suppressor | CCND2, MMP2 | [118] |
miR-30 | Downregulated | Tumor-suppressor | beclin-1, Snail, and ETS2 | [120, 121, 123] |
miR-30 | Overexpressed | Oncogenic | P53 | [124] |
miR-31 | Downregulated | Tumor-suppressor | E2F2s, RhoA, and ITGA5 | [125, 126, 127] |
miR-32 | Overexpressed | Oncogenic | KLF4, KLF2 | [128, 244] |
miR-33 | Downregulated | Tumor-suppressor | CDK6, CCND1, and PIM1 | [129] |
miR-34 | Downregulated | Tumor-suppressor | Bcl-2, Notch, and HMGA2 | [130] |
miR-43 | Overexpressed | Oncogenic | VEZT | [131] |
miR-92 | Downregulated | Tumor-suppressor | EP4, Notch1, SOX4, and FBXW7 | [132, 133, 134] |
miR-93 | Overexpressed | Oncogenic | IFNAR1, PTEN GPC5, and PTG3 | [135, 136, 137, 138] |
miR-95 | Overexpressed | Oncogenic | EMP1 | [139] |
miR-95 | Downregulated | Tumor-suppressor | Slug | [140] |
miR-96 | Overexpressed | Oncogenic | ZDHHC5, KIF26A, and FOXO3 | [141, 142] |
miR-98 | Downregulated | Tumor-suppressor | BCAT1, Treg, and CCND2 | [143, 144, 145] |
miR-100 | Downregulated | Tumor-suppressor | BMPR2, ZBTB7A | [146, 147, 148] |
miR-100 | Overexpressed | Oncogenic | p53, HS3ST2 | [149, 150] |
miR-101 | Downregulated | Tumor-suppressor | ANXA2, ZEB1, SOCS2, PI3K/AKT/mTOR, EZH2, and AMPK | [155, 156, 157, 158, 159] |
miR-103 | Downregulated | Tumor-suppressor | Caveolin-1, RAB10 | [164, 165] |
miR-103 | Overexpressed | Oncogenic | KLF4 | [166] |
miR-105 | Downregulated | Tumor-suppressor | SOX9, YY1 | [167, 168, 169] |
miR-106 | Overexpressed | Oncogenic | NA | [170, 245] |
miR-107 | Overexpressed | Oncogenic | PTEN, NF1, and HIF1α | [171, 172, 173] |
miR-107 | Downregulated | Tumor-suppressor | BDNF | [174] |
miR-122 | Downregulated | Tumor-suppressor | DUSP4, LYN, MYC, MMP-9, and GIT-1 | [176, 177, 178, 179, 180] |
miR-124 | Downregulated | Tumor-suppressor | SPHK1, ROCK1, RAC1, and SP1 | [182, 183, 184] |
miR-125 | Downregulated | Tumor-suppressor | MCL1, BRMS1, VEGF-A, and HER2 | [189, 190, 191, 192] |
miR-126 | Downregulated | Tumor-suppressor | CRKL, VEGF-A, CXCR4, ADAM9, BRCC3, and PIK3R2 | [194, 195, 196, 197, 198, 199] |
miR-127 | Downregulated | Tumor-suppressor | MAPK4, WNT7a, SORT1, and MTDH | [200, 201, 202, 203] |
miR-128 | Downregulated | Tumor-suppressor | PARP2, HMGA2, ZEB1, and ELF4 | [204, 205, 206, 207] |
miR-129 | Downregulated | Tumor-suppressor | P4HA2 | [210] |
miR-130 | Overexpressed | Oncogenic | TGFβR2, C-MYB, and GCNT4 | [211, 212, 213] |
miR-132 | Downregulated | Tumor-suppressor | MUC13, CD44, fibronectin1 (FN1), KIF21B, and PXN | [215, 216, 217, 218] |
miR-134 | Downregulated | Tumor-suppressor | GOLPH3, YY1, and YWHAZ | [219, 220, 221] |
miR-134 | Overexpressed | Oncogenic | PTEN | [222] |
miR-136 | Downregulated | Tumor-suppressor | SORT1, MIEN1 | [202, 226] |
miR-137 | Downregulated | Tumor-suppressor | CDC42, NUP43, and PBX3 | [227, 228, 229] |
miR-138 | Downregulated | Tumor-suppressor | ITGA2, PLAU, FOXC1, and SIRT2 | [230, 231, 232, 233] |
miR-139 | Downregulated | Tumor-suppressor | MYB, MMP11, PRKAA1, ELK1, and SOX4 | [234, 235, 236, 237, 238] |
miR-140 | Downregulated | Tumor-suppressor | ATG5, SOX4, ADAM10, and NDRG3 | [239, 240, 241, 242] |
lncRNA | Expression of lncRNA in Stomach cancer | Target miR | Target gene | Ref. |
---|---|---|---|---|
LINC00242 | Overexpressed | miR-1 | MET | [97] |
UCA1 | Overexpressed | miR-7 | EGFR | [98] |
HULC | Overexpressed | miR-9 | MYH9 | [100] |
HOTAIRM1 | Downregulated | miR-17 | PTEN | [101] |
LINC01939 | Downregulated | miR-17 | EGR2 | [102] |
NEAT1 | Overexpressed | miR-17 | GSK3β | [103] |
CASC2 | Downregulated | miR-19 | NA | [105] |
MEG3 | Downregulated | miR-21 | PTEN | [108] |
CTC-497E21.4 | Overexpressed | miR-22 | NET1 | [109] |
GATA6-AS | Downregulated | miR-22 | FOXO3 | [112] |
TET1–3 | Downregulated | miR-26 | EZH2 | [114] |
LOC400043 | Overexpressed | miR-28 | AKT | [117] |
MEG3 | Overexpressed | miR-29 | CCND2, MMP2 | [119] |
PVT1 | Overexpressed | miR-30 | Snail | [121] |
HNF1A-AS1 | Overexpressed | miR-30 | PI3K/AKT | [122] |
DLEU2 | Overexpressed | miR-30 | ETS2 | [123] |
MIR31HG | Overexpressed | miR-31 | E2F2s, RhoA, and ITGA5 | [127] |
SNHG5 | Downregulated | miR-32 | KLF4 | [128] |
PITPNA-AS1 | Overexpressed | miR-92 | SOX4 | [133] |
MT1JP | Overexpressed | miR-92 | FBXW7 | [134] |
PTENP1 | Downregulated | miR-93 | PTEN, GPC5, and PTG3 | [136, 137, 138] |
TTTY15 | Overexpressed | miR-98 | CCND2 | [145] |
HAGLROS | Overexpressed | miR-100 | mTORC1 signaling pathway | [151] |
MIR100HG | Overexpressed | miR-100 | PI3K/AKT/mTOR pathway | [152, 153, 154] |
LINC01303 | Overexpressed | miR-100 | EZH2 | [159] |
SPRY4-IT1 | Overexpressed | miR-100 | AMPK | [160] |
XIST | Overexpressed | miR-100 | EZH2 | [161] |
SNHG6 | Overexpressed | miR-100 | ZEB1 | [162] |
LINC00943 | Overexpressed | miR-100 | NA | [163] |
LINC00152 | Overexpressed | miR-103 | RAB10 | [165] |
GPC5-AS1 | Downregulated | miR-106 | GPC5 | [137] |
ZFR | Downregulated | miR-107 | PTEN | [171] |
PCAT18 | Downregulated | miR-107 | PTEN | [175] |
LINC01296 | Overexpressed | miR-122 | MMP-9 | [179] |
CRART16 | Overexpressed | miR-122 | VEGFD | [180] |
MALAT1 | Overexpressed | miR-124 | EZH2 | [185] |
LINC00511 | Overexpressed | miR-124 | EZH2 | [186] |
LINC00240 | Overexpressed | miR-124 | DNMT3B | [187] |
HOXA11-AS | Overexpressed | miR-124 | ITGB3 | [188] |
PVT1 | Overexpressed | miR-125 | NA | [193] |
BRCC3 | Overexpressed | miR-126 | BRCC3 | [198] |
PIK3R2 | Overexpressed | miR-126 | PIK3R2 | [199] |
circ_0110389 | Overexpressed | miR-127 | SORT1 | [202] |
circALPL | Overexpressed | miR-127 | MTDH | [203] |
CCL2 | Overexpressed | miR-128 | PARP2 | [204] |
HCP5 | Overexpressed | miR-128 | HMGA2 | [205] |
PCAT1 | Overexpressed | miR-128 | ZEB1 | [206] |
LINC01091 | Overexpressed | miR-128 | ELF4 | [207] |
GACAT2, | Overexpressed | miR-129 | NA | [208] |
GACAT3 | Overexpressed | miR-129 | NA | [208] |
AC130710 | Overexpressed | miR-129 | NA | [209] |
PCGEM1 | Overexpressed | miR-129 | NA | [210] |
MRPL39 | Downregulated | miR-130 | NA | [214] |
XIST | Overexpressed | miR-132 | PXN | [218] |
circPTK2 | Downregulated | miR-134 | PTEN | [222] |
LUCAT1 | Overexpressed | miR-134 | YWHAZ | [221] |
circ_0110389 | Overexpressed | miR-136 | SORT1 | [202] |
circ_100876 | Overexpressed | miR-136 | MIEN1 | [226] |
DSCR8 | Overexpressed | miR-137 | CDC42 | [227] |
NCK1-AS1 | Overexpressed | miR-137 | NUP43 | [228] |
circHECTD1 | Overexpressed | miR-137 | PBX3 | [229] |
UBE2CP3 | Overexpressed | miR-138 | ITGA2 | [230] |
TRPM2-AS | Overexpressed | miR-138 | PLAU | [231] |
MCM3AP-AS1 | Overexpressed | miR-138 | FOXC1 | [232] |
LINC00152 | Overexpressed | miR-138 | SIRT2 | [233] |
SNHG3 | Overexpressed | miR-139 | MYB | [234] |
CTBP1-AS2 | Overexpressed | miR-139 | MMP11 | [235] |
LINC00152 | Overexpressed | miR-139 | PRKAA1 | [236] |
Circ-PTPDC1 | Overexpressed | miR-139 | ELK1 | [237] |
circ_0000218 | Overexpressed | miR-139 | SOX4 | [238] |
CCAT1 | Overexpressed | miR-140 | ATG5 | [239] |
TMPO-AS1 | Overexpressed | miR-140 | SOX4 | [240] |
SNHG1 | Overexpressed | miR-140 | ADAM10 | [241] |
SNHG20 | Overexpressed | miR-140 | NDRG3 | [242] |
2. Conclusion
The current review concludes the vital role of ncRNA (both miRNA and lncRNA) in some digestive system tumors either as an oncogene-promoting cancer viability, invasiveness, proliferation, and metastasis or as a tumor suppressor inhibiting tumorigenicity or inducing apoptosis.
References
- 1.
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Frontiers in Endocrinology. 2018; 9 :402. DOI: 10.3389/fendo.2018.00402 - 2.
Batista PJ, Chang HY. Long noncoding RNAs: Cellular address codes in development and disease. Cell. 2013; 152 (6):1298-1307. DOI: 10.1016/j.cell/2013/02/012 - 3.
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014; 25 (5):666-681. DOI: 10.1016/j.ccr.2014.03.010 - 4.
Forterre A, Komuro H, Aminova S, Harada M. A comprehensive review of cancer microRNA therapeutic delivery strategies. Cancers. 2020; 12 (7):1852. DOI: 10.3390/cancers12071852 - 5.
Tan W, Liu B, Qu S, Liang G, Luo W, Gong C. MicroRNAs and cancer: Key paradigms in molecular therapy. Oncology Letters. 2018; 15 (3):2735-2742. DOI: 10.3892/ol.2017.7638 - 6.
Lendvai G, Szekerczés T, Gyöngyösi B, Schlachter K, Kontsek E, Pesti A, et al. MicroRNA expression in focal nodular hyperplasia in comparison with cirrhosis and hepatocellular carcinoma. Pathology Oncology Research. 2019; 25 (3):1103-1109. DOI: 10.1007/s12253-018-0528-z - 7.
Wang H, Yang G, Yu Y, Peibing Gu PG. MicroRNA-490-3p suppresses the proliferation and invasion of hepatocellular carcinoma cells via targeting TMOD3. Oncology Letters. 2020; 20 (4):1. DOI: 10.3892/ol.2020.11956 - 8.
Han TS, Hur K, Cho HS, Ban HS. Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma. Cancers. 2020; 12 (9):2622. DOI: 10.3390/cancers12092622 - 9.
Guan C, Zhao Y, Wang W, Hu Z, Liu L, Li W, et al. Knockdown of lncRNA SNHG20 suppressed the proliferation of cholangiocarcinoma by sponging miR-520f-3p. Cancer Biotherapy & Radiopharmaceuticals. 2020; 12 (1):1-13. DOI: 10.1089/cbr.2020.4042 - 10.
Li K, Han H, Gu W, Cao C, Zheng P. Long non-coding RNA LINC01963 inhibits progression of pancreatic carcinoma by targeting miR-641/TMEFF2. Biomedicine & Pharmacotherapy. 2020; 129 :110346. DOI: 10.1016/j.biopha.2020.110346 - 11.
Miao H, Lu J, Guo Y, Qiu H, Zhang Y, Yao X, et al. LncRNA TP73-AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA-200a sponging. Journal of Cellular and Molecular Medicine. 2021; 25 (7):3654-3664. DOI: 10.1111/jcmm.16425 - 12.
Ye Z, Fang J, Wang Z, Wang L, Li B, Liu T, et al. Bioinformatics-based analysis of the lncRNA–miRNA–mRNA and TF regulatory networks reveals functional genes in esophageal squamous cell carcinoma. Bioscience Reports. 2020; 40 (8):1-15. DOI: 10.1042/BSR20201727 - 13.
Ghafouri-Fard S, Shoorei H, Dashti S, Branicki W, Taheri M. Expression profile of lncRNAs and miRNAs in esophageal cancer: Implications in diagnosis, prognosis, and therapeutic response. Journal of Cellular Physiology. 2020; 235 (12):9269-9290. DOI: 10.1002/jcp.29825 - 14.
Jin Y, Cao J, Hu X, Cheng H. Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p. Journal of Clinical Laboratory Analysis. 2021; 35 (12):e24106. DOI: 10.1002/jcla.24106 - 15.
Arnal MJ, Arenas ÁF, Arbeloa ÁL. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and eastern countries. World Journal of Gastroenterology WJG. 2015; 21 (26):7933-7943 - 16.
Yang M, Wei L, Sun J, Zhang N, Shen Y, Wang T, et al. Novel implications of microRNAs, long noncoding RNAs and circular RNAs in drug resistance of esophageal cancer. Frontiers in Cell and Development Biology. 2021; 9 :1-14. DOI: 10.3389/fcell.2021.764313 - 17.
Chan JJ, Tay Y. Noncoding RNA: RNA regulatory networks in cancer. International Journal of Molecular Sciences. 2018; 19 (5):1310. DOI: 10.3390/ijms19051310 - 18.
Liu W, Li M, Chen X, Zhu S, Shi H, Zhang D, et al. MicroRNA-1 suppresses proliferation, migration and invasion by targeting Notch2 in esophageal squamous cell carcinoma. Scientific Reports. 2018; 8 (1):5183. DOI: 10.1038/s41598-018-23421-3 - 19.
Yang C, Ning S, Li Z, Qin X, Xu W. miR-22 is down-regulated in esophageal squamous cell carcinoma and inhibits cell migration and invasion. Cancer Cell International. 2014; 14 (1):138. DOI: 10.1186/s12935-014-0138-0 - 20.
Li J, Liang Y, Lv H, Meng H, Xiong G, Guan X, et al. miR-26a and miR-26b inhibit esophageal squamous cancer cell proliferation through suppression of c-MYC pathway. Gene. 2017; 625 :1-9. DOI: 10.1016/j.gene.2017.05.001 - 21.
Wu XZ, Wang KP, Song HJ, Xia JH, Jiang Y, Wang YL. MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression. International Journal of Clinical and Experimental Medicine. 2015; 8 (9):15556-15562 - 22.
Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 2008; 135 (6):1866-1869. DOI: 10.1053/j.gastro.2008.10.074 - 23.
Xu J, Lv H, Zhang B, Xu F, Zhu H, Chen B, et al. miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. Journal of Thoracic Disease. 2019; 11 (7):3015-3029. DOI: 10.21037/jtd.2019.07.50 - 24.
Gao C, Wei J, Tang T, Huang Z. Role of microRNA-33a in malignant cells. Oncology Letters. 2020; 20 (3):2537-2556. DOI: 10.3892/ol.2020.11835 - 25.
Zhou H, Yang L, Xu X, Lu M, Guo R, Li D, et al. miR-34a inhibits esophageal squamous cell carcinoma progression via regulation of FOXM1. Oncology Letters. 2019; 17 (1):706-712. DOI: 10.3892/ol.2018.9593 - 26.
Huang SD, Yuan Y, Zhuang CW, Li BL, Gong DJ, Wang SG, et al. MicroRNA-98 and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Molecular Cancer. 2012; 11 (1):51. DOI: 10.1186/1476-4598-11-51 - 27.
Mei LL, Qiu YT, Huang MB, Wang WJ, Bai J, Shi ZZ. MiR-99a suppresses proliferation, migration and invasion of esophageal squamous cell carcinoma cells through inhibiting the IGF1R signaling pathway. Cancer Biomarkers. 2017; 20 (4):527-537. DOI: 10.3233/CBM-170345 - 28.
Zhou SM, Zhang F, Chen XB, Jun CM, Jing X, Wei DX, et al. miR-100 suppresses the proliferation and tumor growth of esophageal squamous cancer cells via targeting CXCR7. Oncology Reports. 2016; 35 (6):3453-3459. DOI: 10.3892/or.2016.4701 - 29.
Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, He Z, et al. Cyclooxygenase-2, a potential therapeutic target, is regulated by miR-101 in esophageal squamous cell carcinoma. PLoS One. 2015; 10 (11):e0140642. DOI: 10.1371/journal.pone.0140642 - 30.
Sharma P, Saini N, Sharma R. miR-107 functions as a tumor suppressor in human esophageal squamous cell carcinoma and targets Cdc42. Oncology Reports. 2017; 37 (5):3116-3127. DOI: 10.3892/or.2017.5546 - 31.
Wang J, Yu PY, Yu JP, Luo JD, Sun ZQ , Sun F, et al. KIF22 promotes progress of esophageal squamous cell carcinoma cells and is negatively regulated by miR-122. American Journal of Translational Research. 2021; 13 (5):4152-4166 - 32.
Zeng B, Zhang X, Zhao J, Wei Z, Zhu H, Fu M, et al. The role of DNMT1/hsa-miR-124-3p/BCAT1 pathway in regulating growth and invasion of esophageal squamous cell carcinoma. BMC Cancer. 2019; 19 (1):609. DOI: 10.1186/s12885-019-5815-x - 33.
Cheng C, Mao Q , Shi M, Lu H, Shen B, Xiao T, et al. miR-125b prevent the progression of esophageal squamous cell carcinoma through the p38-MAPK signaling pathway. Journal of Gastrointestinal Oncology. 2020; 11 (6):1113-1122. DOI: 10.21037/jgo-20-546 - 34.
Gao X, Wang X, Cai K, Wang W, Ju Q , Yang X, et al. MicroRNA-127 is a tumor suppressor in human esophageal squamous cell carcinoma through the regulation of oncogene FMNL3. European Journal of Pharmacology. 2016; 791 :603-610. DOI: 10.1016/j.ejphar.2016.09.025 - 35.
Zhao L, Li R, Xu S, Li Y, Zhao P, Dong W, et al. Tumor suppressor miR-128-3p inhibits metastasis and epithelial–mesenchymal transition by targeting ZEB1 in esophageal squamous-cell cancer. Acta biochim biophys Sin (Shanghai). 2018; 50 (2):171-180. DOI: 10.1093/abbs/gmx132 - 36.
Li Y, Chen D, Gao X, Li X, Shi G. LncRNA NEAT1 regulates cell viability and invasion in esophageal squamous cell carcinoma through the miR-129/CTBP2 axis. Disease Markers. 2017; 2017 :5314649. DOI: 10.1155/2017/5314649 - 37.
Yin Y, Du L, Li X, Zhang X, Gao Y. miR-133a-3p suppresses cell proliferation, migration, and invasion and promotes apoptosis in esophageal squamous cell carcinoma. Journal of Cellular Physiology. 2019; 234 (8):12757-12770. DOI: 10.1002/jcp.27896 - 38.
Yuan Y, Wang Q , Cao F, Han B, Xu L. MiRNA-134 suppresses esophageal squamous cell carcinoma progression by targeting FOXM1. International Journal of Clinical and Experimental Pathology. 2019; 12 (6):2130-2138 - 39.
Huang HZ, Yin YF, Wan WJ, Xia D, Wang R, Shen XM. Up-regulation of microRNA-136 induces apoptosis and radiosensitivity of esophageal squamous cell carcinoma cells by inhibiting the expression of MUC1. Experimental and Molecular Pathology. 2019; 110 :104278. DOI: 10.1016/j.yexmp.2019.104278 - 40.
Xu S, Li X, Li L, Wang Y, Geng C, Guo F, et al. CTCF-silenced miR-137 contributes to EMT and radioresistance in esophageal squamous cell carcinoma. Cancer Cell International. 2021; 21 (1):155. DOI: 10.1186/s12935-020-01740-8 - 41.
Gong H, Song L, Lin C, Liu A, Lin X, Wu J, et al. Downregulation of miR-138 sustains NF-κB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. Clinical Cancer Research. 2013; 19 (5):1083-1093. DOI: 10.1158/1078-0432.CCR-12-3169 - 42.
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu Y, et al. Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma. PLoS One. 2013; 8 (10):e77068. DOI: 10.1371/journal.pone.0077068 - 43.
Zhang K, Chen J, Song H, Chen LB. SNHG16/miR-140-5p axis promotes esophagus cancer cell proliferation, migration and EMT formation through regulating ZEB1. Oncotarget. 2018; 9 (1):1028-1040. DOI: 10.18632/oncotarget.23178 - 44.
Su C, Han Y, Zhang H, Li Y, Yi L, Wang X, et al. RS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-κB signalling. Journal of Cellular and Molecular Medicine. 2018; 22 (6):3097-3107 - 45.
Song Y, Li J, Zhu Y, Dai Y, Zeng T, Liu L, et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget. 2014; 5 (22):11669-11680. DOI: 10.18632/oncotarget.2581 - 46.
Lu YF, Yu JR, Yang Z, Zhu GX, Gao P, Wang H, et al. Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC). Journal of Experimental & Clinical Cancer Research. 2018; 37 (1):301. DOI: 10.1186/s13046-018-0966-1 - 47.
Li BX, Yu Q , Shi ZL, Li P, Fu S. Circulating microRNAs in esophageal squamous cell carcinoma: Association with locoregional staging and survival. International Journal of Clinical and Experimental Medicine. 2015; 8 (5):7241-7250 - 48.
Xu H, Meng XR, Zhou Y, Wang F. Expression of microRNA-17-5p in esophageal squamous cell carcinoma and its effects on cell proliferation and invasion. Zhonghua Zhong liu za zhi [Zhonghua Zhong Liu Za Zhi]. 2020; 42 (2):105-113. DOI: 10.3760/cma.j.issn.0253-3766.2020.02.004 - 49.
Hirajima S, Komatsu S, Ichikawa D, Takeshita H, Konishi H, Shiozaki A, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. British Journal of Cancer. 2013; 108 (9):1822-1829. DOI: 10.1038/bjc.2013.148 - 50.
Zhong H, Xu Y, Wang J, Cao Q , Hu L, Sun D. Overexpression of microRNA-19a-3p promotes lymph node metastasis of esophageal squamous cell carcinoma via the RAC1/CDC42-PAK1 pathway. Translational Cancer Research. 2021; 10 (6):2694-2706. DOI: 10.21037/tcr-21-254 - 51.
Yu J, Chen S, Niu Y, Liu M, Zhang J, Yang Z, et al. Functional significance and therapeutic potential of miRNA-20b-5p in esophageal squamous cell carcinoma. Molecular Therapy-Nucleic Acids. 2020; 21 :315-331. DOI: 10.1016/j.omtn.2020.05.015 - 52.
Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T, et al. Plasma microRNA profiles: Identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 2016; 7 (38):62034-62048. DOI: 10.18632/oncotarget.11500 - 53.
Maghsudlu M, Farashahi Yazd E, Amiriani T. Increased expression of MiR-27a and MiR-24-2 in esophageal squamous cell carcinoma. Journal of Gastrointestinal Cancer. 2020; 51 (1):227-233. DOI: 10.1007/s12029-019-00232-x - 54.
Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Molecular Biology Reports. 2014; 41 (3):1257-1266. DOI: 10.1007/s11033-013-2970-z - 55.
Zhang J, Yao Y, Li H, Ye S. miR-28-3p inhibits prostate cancer cell proliferation, migration and invasion, and promotes apoptosis by targeting ARF6. Experimental and Therapeutic Medicine. 2021; 22 (5):1205. DOI: 10.3892/etm.2021.10639 - 56.
Gao Y, Yi J, Zhang K, Bai F, Feng B, Wang R, et al. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research. 2017; 36 (1):161. DOI: 10.1186/s13046-017-0622-1 - 57.
Liu YT, Zong D, Jiang XS, Yin L, Wang LJ, Wang TT, et al. miR-32 promotes esophageal squamous cell carcinoma metastasis by targeting CXXC5. Journal of Cellular Biochemistry. 2019; 120 (4):6250-6263. DOI: 10.1002/jcb.27912 - 58.
Li X, Guo S, Min L, Guo Q , Zhang S. miR-92a-3p promotes the proliferation, migration and invasion of esophageal squamous cell cancer by regulating PTEN. International Journal of Molecular Medicine. 2019; 44 (3):973-981. DOI: 10.3892/ijmm.2019.4258 - 59.
Cai Y, Ruan W, Ding J, Wei N, Wang J, Zhang H, et al. miR-93-5p regulates the occurrence and development of esophageal carcinoma epithelial cells by targeting TGFβR2. International Journal of Molecular Medicine. 2021; 47 (3):1. DOI: 10.3892/ijmm.2020.4836 - 60.
Yao L, Zhang Y, Zhu Q , Li X, Zhu S, Gong L, et al. Downregulation of microRNA-1 in esophageal squamous cell carcinoma correlates with an advanced clinical stage and its overexpression inhibits cell migration and invasion. International Journal of Molecular Medicine. 2015; 35 (4):1033-1041. DOI: 10.3892/ijmm.2015.2094 - 61.
Gao DC, Hou B, Zhou D, Liu QX, Zhang K, Lu X, et al. Tumor-derived exosomal miR-103a-2-5p facilitates esophageal squamous cell carcinoma cell proliferation and migration. European Review for Medical and Pharmacological Sciences. 2020; 24 (11):6097-6110. DOI: 10.26355/eurrev_202006_21505 - 62.
He B, Zhang K, Han X, Su C, Zhao J, Wang G, et al. Extracellular vesicle-derived miR-105-5p promotes malignant phenotypes of esophageal squamous cell carcinoma by targeting SPARCL1 via FAK/AKT signaling pathway. Frontiers in Genetics. 2022; 13 :1-14. DOI: 10.3389/fgene.2022.819699 - 63.
Zhang J, Chen D, Liang S, Wang J, Liu C, Nie C, et al. miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC. Oncology Letters. 2018; 15 (4):4619-4626. DOI: 10.3892/ol.2018.7861 - 64.
Li M, Meng X, Li M. MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy. Aging (Albany NY). 2020; 12 (12):12107-12118. DOI: 10.18632/aging.103379 - 65.
Yu T, Cao R, Li S, Fu M, Ren L, Chen W, et al. MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells. BMC Cancer. 2015; 15 (1):29. DOI: 10.1186/s12885-015-1031-5 - 66.
Zhang Y, Ren S, Yuan F, Zhang K, Fan Y, Zheng S, et al. miR-135 promotes proliferation and stemness of oesophageal squamous cell carcinoma by targeting RERG. Artificial Cells Nanomedicine Biotechnology. 2018; 46 (suppl. 2):1210-1219. DOI: 10.1080/21691401.2018.1483379 - 67.
Jiang S, Zhao C, Yang X, Li X, Pan Q , Huang H, et al. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression. International Journal of Molecular Medicine. 2016; 38 (1):113-122. DOI: 10.3892/ijmm.2016.2619 - 68.
Zhang C, Wang L, Yang J, Fu Y, Li H, Xie L, et al. MicroRNA-33a-5p suppresses esophageal squamous cell carcinoma progression via regulation of lncRNA DANCR and ZEB1. European Journal of Pharmacology. 2019; 861 :172590. DOI: 10.1016/j.ejphar.2019.172590 - 69.
Chu J, Jia J, Yang L, Qu Y, Yin H, Wan J, et al. LncRNA MIR31HG functions as a ceRNA to regulate c-met function by sponging miR-34a in esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy. 2020; 128 :110313. DOI: 10.1016/j.biopha.2020.110313 - 70.
Cao X, Xu J, Yue D. LncRNA-SNHG16 predicts poor prognosis and promotes tumor proliferation through epigenetically silencing p21 in bladder cancer. Cancer Gene Therapy. 2018; 25 (1-2):10-17. DOI: 10.1038/s41417-017-0006-x - 71.
Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget. 2014; 5 (8):2276-2292. DOI: 10.18632/oncotarget.1902 - 72.
Wang X, Li M, Wang Z, Han S, Tang X, Ge Y, et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. The Journal of Biological Chemistry. 2015; 290 (7):3925-3935. DOI: 10.1074/jbc.M114.596866 - 73.
Chen M, Liu P, Chen Y, Chen Z, Shen M, Liu X, et al. Long noncoding RNA FAM201A mediates the radiosensitivity of esophageal squamous cell cancer by regulating ATM and mTOR expression via miR-101. Frontiers in Genetics. 2018; 9 :611. DOI: 10.3389/fgene.2018.00611 - 74.
Zhou Z, Huang F. Long non-coding RNA LINC00152 regulates cell proliferation, migration and invasion in esophageal squamous cell carcinoma via miR-107/Rab10 axis. Oncotargets and Therapy. 2019; 12 :8553-8567. DOI: 10.2147/OTT.S221515 - 75.
Wang B, Liang T, Li J. Long noncoding RNA LINC01296 is associated with poor prognosis in ESCC and promotes ESCC cell proliferation, migration and invasion. European Review for Medical and Pharmacological Sciences. 2018; 22 (14):4524-4531. DOI: 10.26355/eurrev_201807_15507 - 76.
Li Z, Qin X, Bian W, Li Y, Shan B, Yao Z, et al. Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis. Journal of Experimental & Clinical Cancer Research. 2019; 38 (1):477. DOI: 10.1186/s13046-019-1473-8 - 77.
Ma J, Fan Y, Feng T, Chen F, Xu Z, Li S, et al. HOTAIR regulates HK2 expression by binding endogenous miR-125 and miR-143 in oesophageal squamous cell carcinoma progression. Oncotarget. 2017; 8 (49):86410-86422. DOI: 10.18632/oncotarget.21195 - 78.
Hong Y, He H, Sui W, Zhang J, Zhang S, Yang D. Long non-coding RNA H1 promotes cell proliferation and invasion by acting as a ceRNA of miR-138 and releasing EZH2 in oral squamous cell carcinoma. International Journal of Oncology. 2018; 52 (3):901-912. DOI: 10.3892/ijo.2018.4247 - 79.
Yan S, Xu J, Liu B, Ma L, Feng H, Tan H, et al. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway. Bioengineered. 2021; 12 (1):682-696. DOI: 10.1080/21655979.2021.1887645 - 80.
Tan Z, Zhou P, Zhu Z, Wang Y, Guo Z, Shen M, et al. Upregulated long non-coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA-7/HOXB13 in esophageal squamous cell carcinoma. International Journal of Molecular Medicine. 2021; 47 (5):1-2. DOI: 10.3892/ijmm.2021.4911 - 81.
Dong Z, Zhang A, Liu S, Lu F, Guo Y, Zhang G, et al. Aberrant methylation-mediated silencing of lncRNA MEG3 functions as a ceRNA in esophageal cancer. Molecular Cancer Research. 2017; 15 (7):800-810. DOI: 10.1158/1541-7786.MCR-16-0385 - 82.
Feng B, Wang G, Liang X, Wu Z, Wang X, Dong Z, et al. 83H-AS1 promotes oesophageal squamous cell carcinoma progression via miR-10a-5p/Girdin axis. Journal of Cellular and Molecular Medicine. 2020; 24 (16):8962-8976 - 83.
Zhao Y, Zhang Q , Liu H, Wang N, Zhang X, Yang S. lncRNA part 1. Oncology Reports. 2021; 45 (3):1118-1132. DOI: 10.3892/or.2021.7931 - 84.
Lin J, Liu Z, Liao S, Li E, Wu X, Zeng W. Elevation of long non-coding RNA GAS5 and knockdown of microRNA-21 up-regulate RECK expression to enhance esophageal squamous cell carcinoma cell radio-sensitivity after radiotherapy. Genomics. 2020; 112 (3):2173-2185. DOI: 10.1016/j.ygeno.2019.12.013 - 85.
Zhang J, Xiao F, Qiang G, Zhang Z, Ma Q , Hao Y, et al. Novel lncRNA panel as for prognosis in esophageal squamous cell carcinoma based on ceRNA network mechanism. Computational and Mathematical Methods in Medicine. 2021; 2021 :8020879. DOI: 10.1155/2021/8020879 - 86.
Jain S, Dhingra S. Pathology of esophageal cancer and Barrett’s esophagus. Annals of Cardiothoracic Surgery. 2017; 6 (2):99-109. DOI: 10.21037/acs.2017.03.06 - 87.
Song JH, Tieu AH, Cheng Y, Ma K, Akshintala VS, Simsek C, et al. Novel long noncoding rna mir205hg functions as an esophageal tumor-suppressive hedgehog inhibitor. Cancers. 2021; 13 (7):1707. DOI: 10.3390/cancers13071707 - 88.
Yu Y, Chen X, Cang S. Cancer-related long noncoding RNAs show aberrant expression profiles and competing endogenous RNA potential in esophageal adenocarcinoma. Oncology Letters. 2019; 18 (5):4798-4808. DOI: 10.3892/ol.2019.10808 - 89.
Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1. Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. 2013; 144 (5):956-966.e4. DOI: 10.1053/j.gastro.2013.01.019 - 90.
Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, et al. Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut. 2014; 63 (6):881-890. DOI: 10.1136/gutjnl-2013-305266 - 91.
Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Molecular Cancer. 2019; 18 (1):141. DOI: 10.1186/s12943-019-1064-5 - 92.
Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, et al. LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany, NY). 2019; 11 (13):4587-4596. DOI: 10.18632/aging.102071 - 93.
Liu D, Wu K, Yang Y, Zhu D, Zhang C, Zhao S. Long noncoding RNA ADAMTS9-AS2 suppresses the progression of esophageal cancer by mediating CDH3 promoter methylation. Molecular Carcinogenesis. 2020; 59 (1):32-44. DOI: 10.1002/mc.23126 - 94.
Pang J, Pan H, Yang C, Meng P, Xie W, Li J, et al. Prognostic value of immune-related multi-IncRNA signatures associated with tumor microenvironment in esophageal cancer. Frontiers in Genetics. 2021; 12 :722601. DOI: 10.3389/fgene.2021.722601 - 95.
Han C, Zhou Y, An Q , Li F, Li D, Zhang X, et al. MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. Tumour Biology. 2015; 36 (9):6715-6723. DOI: 10.1007/s13277-015-3358-6 - 96.
Siemens H, Neumann J, Jackstadt R, Mansmann U, Horst D, Kirchner T, et al. Detection of miR-34a promoter methylation in combination with elevated expression of c-met and beta-catenin predicts distant metastasis of colon cancer. Clinical Cancer Research. 2013; 19 (3):710-720. DOI: 10.1158/1078-0432.CCR-12-1703 - 97.
Deng P, Li K, Gu F, Zhang T, Zhao W, Sun M, et al. LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis. Molecular Medicine. 2021; 27 (1):9. DOI: 10.1186/s10020-020-00259-y - 98.
Yang Z, Shi X, Li C, Wang X, Hou K, Li Z, et al. Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis. Experimental Cell Research. 2018; 368 (2):194-201. DOI: 10.1016/j.yexcr.2018.04.030 - 99.
Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. International Journal of Cancer. 2011; 129 (11):2611-2620. DOI: 10.1002/ijc.25923 - 100.
Liu T, Liu Y, Wei C, Yang Z, Chang W, Zhang X. LncRNA HULC promotes the progression of gastric cancer by regulating miR-9-5p/MYH9 axis. Biomedicine & Pharmacotherapy. 2020; 121 :109607. DOI: 10.1016/j.biopha.2019.109607 - 101.
Lu R, Zhao G, Yang Y, Jiang Z, Cai J, Zhang Z, et al. Long noncoding RNA HOTAIRM1 inhibits cell progression by regulating miR-17-5p/PTEN axis in gastric cancer. Journal of Cellular Biochemistry. 2019; 120 (4):4952-4965. DOI: 10.1002/jcb.27770 - 102.
Chen M, Fan L, Zhang SM, Li Y, Chen P, Peng X, et al. LINC01939 inhibits the metastasis of gastric cancer by acting as a molecular sponge of miR-17-5p to regulate EGR2 expression. Cell Death & Disease. 2019; 10 (2):70. DOI: 10.1038/s41419-019-1344-4 - 103.
Wang CL, Wang D, Yan BZ, Fu JW, Qin L. Long non-coding RNA NEAT1 promotes viability and migration of gastric cancer cell lines through up-regulation of microRNA-17. European Review for Medical and Pharmacological Sciences. 2018; 22 (13):4128-4137. DOI: 10.26355/eurrev_201807_15405 - 104.
Chen YJ, Wu H, Zhu JM, Li XD, Luo SW, Dong L, et al. MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients. Journal of Gastroenterology and Hepatology. 2016; 31 (1):155-163. DOI: 10.1111/jgh.13041 - 105.
Li Y, Lv S, Ning H, Li K, Zhou X, Xv H, et al. Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomedicine & Pharmacotherapy. Dec 2018; 1 (108):1775-1782 - 106.
Fan B, Shen C, Wu M, Zhao J, Guo Q , Luo Y. miR-17-92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study. Medicine. 2018; 97 (35):e12007. DOI: 10.1097/MD.0000000000012007 - 107.
Kim SY, Jeon TY, Choi CI, Kim DH, Kim DH, Kim GH, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. The Journal of Molecular Diagnostics. 2013; 15 (5):661-669. DOI: 10.1016/j.jmoldx.2013.04.004 - 108.
Dan J, Wang J, Wang Y, Zhu M, Yang X, Peng Z, et al. LncRNA-MEG3 inhibits proliferation and metastasis by regulating miRNA-21 in gastric cancer. Biomedicine & Pharmacotherapy. 2018; 99 :931-938. DOI: 10.1016/j.biopha.2018.01.164 - 109.
Zong W, Feng W, Jiang Y, Cao Y, Ke Y, Shi X, et al. LncRNA CTC-497E21. 4 promotes the progression of gastric cancer via modulating miR-22/NET1 axis through RhoA signaling pathway. Gastric Cancer. 2020; 23 (2):228-240 - 110.
Dong X, Liu Y. Expression and significance of miR-24 and miR-101 in patients with advanced gastric cancer. Oncology Letters. 2018; 16 (5):5769-5774. DOI: 10.3892/ol.2018.9324 - 111.
Nho RS, Hergert P. FoxO3a and disease progression. World Journal of Biological Chemistry. 2014; 5 (3):346-354. DOI: 10.4331/wjbc.v5.i3.346 - 112.
Li D, Wang T, Lai J, Zhang T, Zhu X, Zeng D, et al. Long non-coding RNA GATA6-AS inhibits gastric cancer cell proliferation by downregulating microRNA-25-3p. Oncology Letters. 2019; 18 (5):4639-4644. DOI: 10.3892/ol.2019.10803 - 113.
Ding K, Wu Z, Wang N, Wang X, Wang Y, Qian P, et al. MiR-26a performs converse roles in proliferation and metastasis of different gastric cancer cells via regulating of PTEN expression. Pathology, Research and Practice. 2017; 213 (5):467-475. DOI: 10.1016/j.prp.2017.01.026 - 114.
Deng M, Zhang R, He Z, Qiu Q , Lu X, Yin J, et al. TET-mediated sequestration of miR-26 drives EZH2 expression and gastric carcinogenesis. Cancer Research. 2017; 77 (22):6069-6082. DOI: 10.1158/0008-5472.CAN-16-2964 - 115.
Song B, Yan G, Hao H, Yang B. rs11671784 G/a and rs895819 a/G polymorphisms inversely affect gastric cancer susceptibility and miR-27a expression in a Chinese population. Medical Science Monitor. 2014; 20 :2318-2326. DOI: 10.12659/MSM.892499 - 116.
Xiao F, Cheng Z, Wang P, Gong B, Huang H, Xing Y, et al. MicroRNA-28-5p inhibits the migration and invasion of gastric cancer cells by suppressing AKT phosphorylation. Oncology Letters. 2018; 15 (6):9777-9785. DOI: 10.3892/ol.2018.8603 - 117.
Militello G, Weirick T, John D, Döring C, Dimmeler S, Uchida S. Screening and validation of lncRNAs and circRNAs as miRNA sponges. Briefings in Bioinformatics. 2017; 18 (5):780-788. DOI: 10.1093/bib/bbw053 - 118.
Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis. 2014; 35 (2):497-506. DOI: 10.1093/carcin/bgt337 - 119.
Wei GH, Wang X. lncRNA MEG3 inhibit proliferation and metastasis of gastric cancer via p53 signaling pathway. European Review for Medical and Pharmacological Sciences. 2017; 21 (17):3850-3856 - 120.
Du X, Liu B, Luan X, Cui Q , Li L. miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Experimental and Therapeutic Medicine. 2018; 15 (1):599-605. DOI: 10.3892/etm.2017.5354 - 121.
Wang L, Xiao B, Yu T, Gong L, Wang Y, Zhang X, et al. lncRNA PVT1 promotes the migration of gastric cancer by functioning as ceRNA of miR-30a and regulating snail. Journal of Cellular Physiology. 2021; 236 (1):536-548. DOI: 10.1002/jcp.29881 - 122.
Liu HT, Ma RR, Lv BB, Zhang H, Shi DB, Guo XY, et al. LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer. British Journal of Cancer. 2020; 122 (12):1825-1836. DOI: 10.1038/s41416-020-0836-4 - 123.
Han S, Qi Y, Xu Y, Wang M, Wang J, Wang J, et al. lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p. Cancer Cell International. 2021; 21 (1):376. DOI: 10.1186/s12935-021-02074-9 - 124.
Wang J, Jiao Y, Cui L, Jiang L. miR-30 functions as an oncomir in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway. Bioscience, Biotechnology, and Biochemistry. 2017; 81 (1):119-126. DOI: 10.1080/09168451.2016.1238294 - 125.
Wang H, Zhang X, Liu Y, Ni Z, Lin Y, Duan Z, et al. Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2. Oncotarget. 2016; 7 (24):36577 - 126.
Korourian A, Roudi R, Shariftabrizi A, Madjd Z. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Experimental Biology and Medicine. 2017; 242 (18):1842-1847 - 127.
Zhang XB, Song L, Wen HJ, Bai XX, Li ZJ, Ma LJ. Upregulation of microRNA-31 targeting integrin α5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells. Tumor Biology. 2016; 37 (6):8317-8325 - 128.
Zhao L, Han T, Li Y, Sun J, Zhang S, Liu Y, et al. The lncRNA SNHG5/miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. The FASEB Journal. 2017; 31 (3):893-903. DOI: 10.1096/fj.201600994R - 129.
Wang Y, Zhou X, Shan B, Han J, Wang F, Fan X, et al. Downregulation of microRNA-33a promotes cyclin-dependent kinase 6, cyclin D1 and PIM1 expression and gastric cancer cell proliferation. Molecular Medicine Reports. 2015; 12 (5):6491-6500. DOI: 10.3892/mmr.2015.4296 - 130.
Ji Q , Hao X, Meng Y, Zhang M, DeSano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008; 8 (1):266. DOI: 10.1186/1471-2407-8-266 - 131.
Guo X, Jing C, Li L, Zhang L, Shi Y, Wang J, et al. Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. Biochemical and Biophysical Research Communications. 2011; 404 (2):622-627. DOI: 10.1016/j.bbrc.2010.12.026 - 132.
Shin VY, Siu MT, Liu X, Ng EKO, Kwong A, Chu KM. MiR-92 suppresses proliferation and induces apoptosis by targeting EP4/Notch1 axis in gastric cancer. Oncotarget. 2018; 9 (36):24209-24220. DOI: 10.18632/oncotarget.24819 - 133.
Liu L, Dai A, Zhang Z, Ning M, Han D, Li L, et al. LncRNA PITPNA-AS1 promotes gastric cancer by increasing SOX4 expression via inhibition of miR-92a-3p. Aging (Albany, NY). 2021; 13 (17):21191-21201. DOI: 10.18632/aging.203403 - 134.
Zhang Y, Guo L, Li Y, Feng G, Teng F, Li W, et al. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer. Molecular Cancer. 2018; 17 (1):1-11. DOI: 10.1186/s12943-017-0753-1 - 135.
Ma DH, Li BS, Liu JJ, Xiao YF, Yong X, Wang SM, et al. miR-93-5p/IFNAR1 axis promotes gastric cancer metastasis through activating the STAT3 signaling pathway. Cancer Letters. 2017; 408 :23-32. DOI: 10.1016/j.canlet.2017.08.017 - 136.
Zhang R, Guo Y, Ma Z, Ma G, Xue Q , Li F, et al. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer. Oncotarget. 2017; 8 (16):26079-26089. DOI: 10.18632/oncotarget.15317 - 137.
Bo G, Liu Y, Li W, Wang L, Zhao L, Tong D, et al. The novel lncRNA GPC5-AS1 stabilizes GPC5 mRNA by competitively binding with miR-93/106a to suppress gastric cancer cell proliferation. Aging (Albany, NY). 2022; 14 (4):1767-1781. DOI: 10.18632/aging.203901 - 138.
Zhang XY, Zhuang HW, Wang J, Shen Y, Bu YZ, Guan BG, et al. Long noncoding RNA CA3-AS1 suppresses gastric cancer migration and invasion by sponging miR-93-5p and targeting BTG3. Gene Therapy. 2020; 29 (9):1-9. DOI: 10.1038/s41434-020-00201-1 - 139.
Ni Q , Zhang Y, Tao R, Li X, Zhu J. MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling. Aging (Albany, NY). 2021; 13 (6):8665-8687. DOI: 10.18632/aging.202679 - 140.
Zhang W, Sun J, Chen J, Xu C, Zhang L. Downregulation of miR-95 in gastric cancer promotes EMT via regulation of slug, thereby promoting migration and invasion. Oncology Reports. 2019; 41 (2):1395-1403. DOI: 10.3892/or.2018.6911 - 141.
Zhou HY, Wu CQ , Bi EX. MiR-96-5p inhibition induces cell apoptosis in gastric adenocarcinoma. World Journal of Gastroenterology. 2019; 25 (47):6823-6834. DOI: 10.3748/wjg.v25.i47.6823 - 142.
Ma RR, Zhang H, Chen HF, Zhang GH, Tian YR, Gao P. MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer. Oncogene. 2021; 40 (14):2524-2538. DOI: 10.1038/s41388-020-01610-7 - 143.
Zhan P, Shu X, Chen M, Sun L, Yu L, Liu J, et al. miR-98-5p inhibits gastric cancer cell stemness and chemoresistance by targeting branched-chain aminotransferases 1. Life Sciences. 2021; 276 :119405. DOI: 10.1016/j.lfs.2021.119405 - 144.
Xu QF, Peng HP, Lu XR, Hu Y, Xu ZH, Xu JK. Oleanolic acid regulates the Treg/Th17 imbalance in gastric cancer by targeting IL-6 with miR-98-5p. Cytokine. 2021; 148 :155656. DOI: 10.1016/j.cyto.2021.155656 - 145.
Wen X, Han W, Liu C. Long non-coding RNA TTTY15 silencing inhibits gastric cancer progression by sponging microRNA-98-5p to down-regulate cyclin D2 expression. Bioengineered. 2022; 13 (3):7380-7391. DOI: 10.1080/21655979.2022.2047398 - 146.
Peng CW, Yue LX, Zhou YQ , Tang S, Kan C, Xia LM, et al. miR-100-3p inhibits cell proliferation and induces apoptosis in human gastric cancer through targeting to BMPR2. Cancer Cell International. 2019; 19 (1):354. DOI: 10.1186/s12935-019-1060-2 - 147.
Shi DB, Wang YW, Xing AY, Gao JW, Zhang H, Guo XY, et al. C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Letters. 2015; 369 (2):376-385. DOI: 10.1016/j.canlet.2015.08.029 - 148.
Cao Y, Song J, Ge J, Song Z, Chen J, Wu C. MicroRNA-100 suppresses human gastric cancer cell proliferation by targeting CXCR7. Oncology Letters. 2018; 15 (1):453-458. DOI: 10.3892/ol.2017.7305 - 149.
Gong Y, Yang G, Wang Q , Wang Y, Zhang X. NME2 is a master suppressor of apoptosis in gastric cancer cells via transcriptional regulation of miR-100 and other survival factors. Molecular Cancer Research. 2020; 18 (2):287-299. DOI: 10.1158/1541-7786.MCR-19-0612 - 150.
Yang G, Gong Y, Wang Q , Wang Y, Zhang X. The role of miR-100-mediated notch pathway in apoptosis of gastric tumor cells. Cellular Signalling. 2015; 27 (6):1087-1101. DOI: 10.1016/j.cellsig.2015.02.013 - 151.
Chen JF, Wu P, Xia R, Yang J, Huo XY, Gu DY, et al. STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy. Molecular Cancer. 2018; 17 (1):6. DOI: 10.1186/s12943-017-0756-y - 152.
Li J, Xu Q , Wang W, Sun S. MIR100HG: A credible prognostic biomarker and an oncogenic lncRNA in gastric cancer. Bioscience Reports. 2019; 39 (4):1-8. DOI: 10.1042/BSR20190171 - 153.
Zheng Y, Tan K, Huang H. Retracted: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in colorectal cancer cells via sponging miR-100 to target ATG5 expression. Journal of Cellular Biochemistry. 2019; 120 (3):3922-3933. DOI: 10.1002/jcb.27676 - 154.
Zhang W, Zhang Y, Xi S. Upregulation of lncRNA HAGLROS enhances the development of nasopharyngeal carcinoma via modulating miR-100/ATG14 axis-mediated PI3K/AKT/mTOR signals. Artificial Cells Nanomedicine Biotechnology. 2019; 47 (1):3043-3052. DOI: 10.1080/21691401.2019.1640233 - 155.
Bao J, Xu Y, Wang Q , Zhang J, Li Z, Li D, et al. miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomedicine & Pharmacotherapy. 2017; 92 :1030-1037. DOI: 10.1016/j.biopha.2017.06.011 - 156.
Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, et al. Low plasma levels of miR-101 are associated with tumor progression in gastric cancer. Oncotarget. 2017; 8 (63):106538-106550. DOI: 10.18632/oncotarget.20860 - 157.
Zhou X, Xia Y, Li L, Zhang G. MiR-101 inhibits cell growth and tumorigenesis of helicobacter pylori related gastric cancer by repression of SOCS2. Cancer Biology & Therapy. 2015; 16 (1):160-169. DOI: 10.4161/15384047.2014.987523 - 158.
Riquelme I, Tapia O, Leal P, Sandoval A, Varga MG, Letelier P, et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cellular Oncology (Dordrecht). 2016; 39 (1):23-33. DOI: 10.1007/s13402-015-0247-3 - 159.
Cao C, Xu Y, Du K, Mi C, Yang C, Xiang L, et al. LINC01303 functions as a competing endogenous RNA to regulate EZH2 expression by sponging miR-101-3p in gastric cancer. Journal of Cellular and Molecular Medicine. 2019; 23 (11):7342-7348 - 160.
Cao S, Lin L, Xia X, Wu H. lncRNA SPRY4-IT1 regulates cell proliferation and migration by sponging miR-101-3p and regulating AMPK expression in gastric cancer. Molecular Therapy-Nucleic Acids. 2019; 17 :455-464. DOI: 10.1016/j.omtn.2019.04.030 - 161.
Chen DL, Ju HQ , Lu YX, Chen LZ, Zeng ZL, Zhang DS, et al. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. Journal of Experimental & Clinical Cancer Research. 2016; 35 (1):142. DOI: 10.1186/s13046-016-0420-1 - 162.
Yan K, Tian J, Shi W, Xia H, Zhu Y. LncRNA SNHG6 is associated with poor prognosis of gastric cancer and promotes cell proliferation and EMT through epigenetically silencing p27 and sponging miR-101-3p. Cellular Physiology and Biochemistry. 2017; 42 (3):999-1012. DOI: 10.1159/000478682 - 163.
Xu Y, Ji T, An N, Wang X, Zhang H, Xu F. LINC00943 is correlated with gastric cancer and regulates cancer cell proliferation and chemosensitivity via hsa-miR-101-3p. International Journal of Clinical Oncology. 2021; 26 (9):1650-1660. DOI: 10.1007/s10147-021-01945-5 - 164.
Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X, et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biology. 2015; 36 (4):2277-2285. DOI: 10.1007/s13277-014-2835-7 - 165.
Wei F, Wang Y, Zhou Y, Li Y. Long noncoding RNA CYTOR triggers gastric cancer progression by targeting miR-103/RAB10. Acta Biochimica et Biophysica Sinica (Shanghai). 2021; 53 (8):1044-1054. DOI: 10.1093/abbs/gmab071 - 166.
Zheng J, Liu Y, Qiao Y, Zhang L, Lu S. miR-103 promotes proliferation and metastasis by targeting KLF4 in gastric cancer. International Journal of Molecular Sciences. 2017; 18 (5):910. DOI: 10.3390/ijms18050910 - 167.
Shang JC, Yu GZ, Ji ZW, Wang XQ , Xia L. MiR-105 inhibits gastric cancer cells metastasis, epithelial-mesenchymal transition by targeting SOX9. European Review for Medical and Pharmacological Sciences. 2019; 23 (14):6160-6169. DOI: 10.26355/eurrev_201907_18429 - 168.
Jin M, Zhang GW, Shan CL, Zhang H, Wang ZG, Liu SQ , et al. Up-regulation of miRNA-105 inhibits the progression of gastric carcinoma by directly targeting SOX9. European Review for Medical and Pharmacological Sciences. 2019; 23 (9):3779-3789. DOI: 10.26355/eurrev_201905_17804 - 169.
Zhou GQ , Han F, Shi ZL, Yu L, Li XF, Yu C, et al. DNMT3A-mediated down-regulation of microRNA-105 promotes gastric cancer cell proliferation. European Review for Medical and Pharmacological Sciences. 2017; 21 (15):3377-3383 - 170.
Hou X, Zhang M, Qiao H. Diagnostic significance of miR-106a in gastric cancer. International Journal of Clinical and Experimental Pathology. 2015; 8 (10):13096-13101 - 171.
Liu T, Liu S, Xu Y, Shu R, Wang F, Chen C, et al. Circular RNA-ZFR inhibited cell proliferation and promoted apoptosis in gastric cancer by sponging miR-130a/miR-107 and modulating PTEN. Cancer Research and Treatment. 2018; 50 (4):1396-1417. DOI: 10.4143/crt.2017.537 - 172.
Wang S, Ma G, Zhu H, Lv C, Chu H, Tong N, et al. miR-107 regulates tumor progression by targeting NF1 in gastric cancer. Scientific Reports. 2016; 6 (1):36531. DOI: 10.1038/srep36531 - 173.
Ayremlou N, Mozdarani H, Mowla SJ, Delavari A. Increased levels of serum and tissue miR-107 in human gastric cancer: Correlation with tumor hypoxia. Cancer Biomarkers. 2015; 15 (6):851-860. DOI: 10.3233/CBM-150529 - 174.
Wei J, Xu H, Wei W, Wang Z, Zhang Q , De W, et al. circHIPK3 promotes cell proliferation and migration of gastric cancer by sponging miR-107 and regulating BDNF expression. Oncotargets and Therapy. 2020; 13 :1613-1624. DOI: 10.2147/OTT.S226300 - 175.
Chen P, Zhao X, Wang H, Zheng M, Wang Q , Chang W. The down-regulation of lncRNA PCAT18 promotes the progression of gastric cancer via MiR-107/PTEN/PI3K/AKT signaling pathway. Oncotargets and Therapy. 2019; 12 :11017-11031. DOI: 10.2147/OTT.S225235 - 176.
Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biology & Therapy. 2018; 19 (5):427-435. DOI: 10.1080/15384047.2018.1423925 - 177.
Meng L, Chen Z, Jiang Z, Huang T, Hu J, Luo P, et al. MiR-122-5p suppresses the proliferation, migration, and invasion of gastric cancer cells by targeting LYN. Acta Biochimica et Biophysica Sinica (Shanghai). 2020; 52 (1):49-57. DOI: 10.1093/abbs/gmz141 - 178.
Pei ZJ, Zhang ZG, Hu AX, Yang F, Gai Y. miR-122-5p inhibits tumor cell proliferation and induces apoptosis by targeting MYC in gastric cancer cells. Die Pharmazie. 2017; 72 (6):344-347. DOI: 10.1691/ph.2017.6404 - 179.
Qin QH, Yin ZQ , Li Y, Wang BG, Zhang MF. Long intergenic noncoding RNA 01296 aggravates gastric cancer cells progress through miR-122/MMP-9. Biomedicine & Pharmacotherapy. 2018; 97 :450-457. DOI: 10.1016/j.biopha.2017.10.066 - 180.
Jiao Y, Zhang L, Li J, He Y, Zhang X, Li J. Exosomal miR-122-5p inhibits tumorigenicity of gastric cancer by downregulating GIT1. The International Journal of Biological Markers. 2021; 36 (1):36-46. DOI: 10.1177/1724600821990677 - 181.
Zhang J, Pang X, Lei L, Zhang J, Zhang X, Chen Z, et al. LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression. Aging (Albany, NY). 2022; 14 (9):4137-4157. DOI: 10.18632/aging.204078 - 182.
Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. The Journal of Pathology. 2012; 227 (4):470-480. DOI: 10.1002/path.4030 - 183.
Hu CB, Li QL, Hu JF, Zhang Q , Xie JP, Deng L. miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pacific Journal of Cancer Prevention. 2014; 15 (16):6543-6546. DOI: 10.7314/apjcp.2014.15.16.6543 - 184.
Liu F, Hu H, Zhao J, Zhang Z, Ai X, Tang L, et al. miR-124-3p acts as a potential marker and suppresses tumor growth in gastric cancer. Biomedicine Reports. 2018; 9 (2):147-155. DOI: 10.3892/br.2018.1113 - 185.
Zhu B, Cui H, Xu W. Hydrogen inhibits the proliferation and migration of gastric cancer cells by modulating lncRNA MALAT1/miR-124-3p/EZH2 axis. Cancer Cell International. 2021; 21 (1):70. DOI: 10.1186/s12935-020-01743-5 - 186.
Huang HG, Tang XL, Huang XS, Zhou L, Hao YG, Zheng YF. Long noncoding RNA LINC00511 promoted cell proliferation and invasion via regulating miR-124-3p/EZH2 pathway in gastric cancer. European Review for Medical and Pharmacological Sciences. 2020; 24 (8):4232-4245. DOI: 10.26355/eurrev_202004_21003 - 187.
Li Y, Yan J, Wang Y, Wang C, Zhang C, Li G. LINC00240 promotes gastric cancer cell proliferation, migration and EMT via the miR-124-3p/DNMT3B axis. Cell Biochemistry and Function. 2020; 38 (8):1079-1088. DOI: 10.1002/cbf.3551 - 188.
Cheng Y, Yang L, Shi G, Chen P, Li L, Fang H, et al. Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk. Cancer Cell International. 2021; 21 (1):1. DOI: 10.1186/s12935-020-01646-5 - 189.
Wu S, Liu F, Xie L, Peng Y, Lv X, Zhu Y, et al. miR-125b suppresses proliferation and invasion by targeting MCL1 in gastric cancer. BioMed Research International. 2015; 2015 :365273. DOI: 10.1155/2015/365273 - 190.
Cao Y, Tan S, Tu Y, Zhang G, Liu Y, Li D, et al. MicroRNA-125a-5p inhibits invasion and metastasis of gastric cancer cells by targeting BRMS1 expression. Oncology Letters. 2018; 15 (4):5119-5130. DOI: 10.3892/ol.2018.7983 - 191.
Dai J, Wang J, Yang L, Xiao Y, Ruan Q. miR-125a regulates angiogenesis of gastric cancer by targeting vascular endothelial growth factor a. International Journal of Oncology. 2015; 47 (5):1801-1810. DOI: 10.3892/ijo.2015.3171 - 192.
Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V, et al. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Human Pathology. 2013; 44 (9):1804-1810. DOI: 10.1016/j.humpath.2013.01.023 - 193.
Niu J, Song X, Zhang X. Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells. Oncology Letters. 2020; 19 (2):1261-1266. DOI: 10.3892/ol.2019.11195 - 194.
Wang J, Chen X, Li P, Su L, Yu B, Cai Q , et al. CRKL promotes cell proliferation in gastric cancer and is negatively regulated by miR-126. Chemico-Biological Interactions. 2013; 206 (2):230-238. DOI: 10.1016/j.cbi.2013.09.003 - 195.
Chen H, Li L, Wang S, Lei Y, Ge Q , Lv N, et al. Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget. 2014; 5 (23):11873-11885. DOI: 10.18632/oncotarget.2662 - 196.
Xiao J, Lai H, Wei SH, Ye ZS, Gong FS, Chen LC. Lnc RNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR 4 and RhoA signaling pathway. Cancer Medicine. 2019; 8 (15):6768-6779. DOI: 10.1002/cam4.1302 - 197.
Wang J, Zhou Y, Fei X, Chen X, Yan J, Liu B, et al. ADAM9 functions as a promoter of gastric cancer growth which is negatively and post-transcriptionally regulated by miR-126. Oncology Reports. 2017; 37 (4):2033-2040. DOI: 10.3892/or.2017.5460 - 198.
Hu Y, Zhang Y, Ding M, Xu R. Long noncoding RNA TMPO-AS1/miR-126-5p/BRCC3 axis accelerates gastric cancer progression and angiogenesis via activating PI3K/Akt/mTOR pathway. Journal of Gastroenterology and Hepatology. 2021; 36 (7):1877-1888 - 199.
Yan J, Dang Y, Liu S, Zhang Y, Zhang G. LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes. Tumor Biology. 2016; 37 (12):16345-16355 - 200.
Guo LH, Li H, Wang F, Yu J, He JS. The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. International Journal of Molecular Sciences. 2013; 14 (7):14171-14184. DOI: 10.3390/ijms140714171 - 201.
Wang L, Wang X, Jiang X. miR-127 suppresses gastric cancer cell migration and invasion via targeting Wnt7a. Oncology Letters. 2019; 17 (3):3219-3226. DOI: 10.3892/ol.2019.9955 - 202.
Liang M, Yao W, Shi B, Zhu X, Cai R, Yu Z, et al. Circular RNA hsa_circ_0110389 promotes gastric cancer progression through upregulating SORT1 via sponging miR-127-5p and miR-136-5p. Cell Death & Disease. 2021; 12 (7):639. DOI: 10.1038/s41419-021-03903-5 - 203.
Wu P, Ye D, Li J, Yan F, Jin X, Zhang Z, et al. circALPL sponges miR-127 to promote gastric cancer progression by enhancing MTDH expression. Journal of Cancer. 2021; 12 (16):4924-4932. DOI: 10.7150/jca.49942 - 204.
Ma L, Jiang Y, Wu N. Long non-coding RNA CCL2 promoted gastric cancer function via miR-128/PARP2 signal pathway. Bioengineered. 2022; 13 (1):1602-1611. DOI: 10.1080/21655979.2021.2020548 - 205.
Liang L, Kang H, Jia J. HCP5 contributes to cisplatin resistance in gastric cancer through miR-128/HMGA2 axis. Cell Cycle. 2021; 20 (11):1080-1090. DOI: 10.1080/15384101.2021.1924948 - 206.
Guo Y, Yue P, Wang Y, Chen G, Li Y. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis. Biomedicine & Pharmacotherapy. 2019; 118 :109255. DOI: 10.1016/j.biopha.2019.109255 - 207.
Wang Q , Zhang C, Cao S, Zhao H, Jiang R, Li Y. Tumor-derived exosomes orchestrate the microRNA-128-3p/ELF4/CDX2 axis to facilitate the growth and metastasis of gastric cancer via delivery of LINC01091. Cell Biology and Toxicology. 2022:1-8. DOI: 10.1007/s10565-022-09728-y - 208.
Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L, et al. lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. Tumour Biology. 2014; 35 (10):9701-9706. DOI: 10.1007/s13277-014-2274-5 - 209.
Zhang T, Piao HY, Guo S, Zhao Y, Wang Y, Zheng ZC, et al. LncRNA PCGEM1 enhances metastasis and gastric cancer invasion through targeting of miR-129-5p to regulate P4HA2 expression. Experimental and Molecular Pathology. 2020; 116 :104487. DOI: 10.1016/j.yexmp.2020.104487 - 210.
Chen S, Li P, Xiao B, Guo J. Long noncoding RNA HMlincRNA717 and AC130710 have been officially named as gastric cancer associated transcript 2 (GACAT2) and GACAT3, respectively. Tumor Biology. 2014; 35 (9):8351-8352 - 211.
Duan J, Zhang H, Qu Y, Deng T, Huang D, Liu R, et al. Onco-miR-130 promotes cell proliferation and migration by targeting TGFβR2 in gastric cancer. Oncotarget. 2016; 7 (28):44522-44533. DOI: 10.18632/oncotarget.9936 - 212.
Yang H, Zhang H, Ge S, Ning T, Bai M, Li J, et al. Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells. Molecular Therapy. 2018; 26 (10):2466-2475. DOI: 10.1016/j.ymthe.2018.07.023 - 213.
Hu W, Zheng X, Liu J, Zhang M, Liang Y, Song M. MicroRNA MiR-130a-3p promotes gastric cancer by targeting glucosaminyl N-acetyl transferase 4 (GCNT4) to regulate the TGF-β1/SMAD3 pathway. Bioengineered. 2021; 12 (2):11634-11647. DOI: 10.1080/21655979.2021.1995099 - 214.
Yu MJ, Zhao N, Shen H, Wang H. Long noncoding RNA MRPL39 inhibits gastric cancer proliferation and progression by directly targeting miR-130. Genetic Testing and Molecular Biomarkers. 2018; 22 (11):656-663. DOI: 10.1089/gtmb.2018.0151 - 215.
He L, Qu L, Wei L, Chen Y, Suo J. Reduction of miR-132-3p contributes to gastric cancer proliferation by targeting MUC13. Molecular Medicine Reports. 2017; 15 (5):3055-3061. DOI: 10.3892/mmr.2017.6347 - 216.
Liu F, Cheng Z, Li X, Li Y, Zhang H, Li J, et al. A novel Pak1/ATF2/miR-132 signaling axis is involved in the hematogenous metastasis of gastric cancer cells. Molecular Therapy-Nucleic Acids. 2017; 8 :370-382. DOI: 10.1016/j.omtn.2017.07.005 - 217.
Liu B, Qiang L, Guan B, Ji Z. Targeting kinesin family member 21B by miR-132-3p represses cell proliferation, migration and invasion in gastric cancer. Bioengineered. 2022; 13 (4):9006-9018. DOI: 10.1080/21655979.2022.2054755 - 218.
Li P, Wang L, Li P, Hu F, Cao Y, Tang D, et al. Silencing lncRNA XIST exhibits antiproliferative and proapoptotic effects on gastric cancer cells by up-regulating microRNA-132 and down-regulating PXN. Aging. 2021; 13 (10):14469-14481. DOI: 10.18632/aging.103635 - 219.
Liu Y, Sun Y, Zhao A. MicroRNA-134 suppresses cell proliferation in gastric cancer cells via targeting of GOLPH3. Oncology Reports. 2017; 37 (4):2441-2448. DOI: 10.3892/or.2017.5488 - 220.
Zhong BZ, Wang Q , Liu F, He JL, Xiong Y, Cao J. Effects of mir-384 and mir-134-5p acting on yy1 signaling transduction on biological function of gastric cancer cells. Oncotargets and Therapy. 2020; 13 :9631-9641. DOI: 10.2147/OTT.S259988 - 221.
Chi J, Liu T, Shi C, Luo H, Wu Z, Xiong B, et al. Long non-coding RNA LUCAT1 promotes proliferation and invasion in gastric cancer by regulating miR-134-5p/YWHAZ axis. Biomedicine & Pharmacotherapy. 2019; 118 :109201. DOI: 10.1016/j.biopha.2019.109201 - 222.
Fan HN, Zhao XY, Liang R, Chen XY, Zhang J, Chen NW, et al. CircPTK2 inhibits the tumorigenesis and metastasis of gastric cancer by sponging miR-134-5p and activating CELF2/PTEN signaling. Pathology-Research and Practice. 2021; 227 :153615 - 223.
Yan LH, Chen ZN, Li-Li CJ, Wei WE, Mo XW, et al. miR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget. 2016; 7 (43):70699-70714. DOI: 10.18632/oncotarget.12208 - 224.
Wu Y, Hu G, Wu R, Gong N. High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer. Life Sciences. 2020; 257 :118133. DOI: 10.1016/j.lfs.2020.118133 - 225.
He Y, Wu L, Dai Y, Li J, Liu S. MicroRNA-135 inhibits gastric cancer metastasis by targeting SMAD2. European Review for Medical and Pharmacological Sciences. 2019; 23 (21):9436-9444. DOI: 10.26355/eurrev_201911_19437 - 226.
Yu X, Xiao W, Song H, Jin Y, Xu J. Liu X CircRNA_100876 sponges miR-136 to promote proliferation and metastasis of gastric cancer by upregulating MIEN1 expression. Gene. 2020; 748 :144678. DOI: 10.1016/j.gene.2020.144678 - 227.
Chen Z, Xu C, Pan X, Cheng G, Liu M, Li J, et al. lncRNA DSCR8 mediates miR-137/Cdc42 to regulate gastric cancer cell proliferation, invasion, and cell cycle as a competitive endogenous RNA. Molecular Therapy-Oncolytics. 2021; 22 :468-482. DOI: 10.1016/j.omto.2021.05.010 - 228.
Li W, Duan J, Shi W, Lei L, Lv P. Long non-coding RNA NCK1-AS1 serves an oncogenic role in gastric cancer by regulating miR-137/NUP43 axis. Oncotargets and Therapy. 2020; 13 :9929-9939. DOI: 10.2147/OTT.S259336 - 229.
Lu Y, Li L, Li L, Wu G, Liu G. Circular RNA circHECTD1 prevents Diosbulbin-B-sensitivity via miR-137/PBX3 axis in gastric cancer. Cancer Cell International. 2021; 21 (1):264. DOI: 10.1186/s12935-021-01957-1 - 230.
Li D, She J, Hu X, Zhang M, Sun R, Qin S. The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA–RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis. Oncogene. 2021; 40 (35):5403-5415. DOI: 10.1038/s41388-021-01948-6 - 231.
Sun J, Zhou F, Xue J, Ji C, Qu Y, Pan Y. Long non-coding RNA TRPM2-AS regulates microRNA miR-138-5p and PLAU (plasminogen activator, urokinase) to promote the progression of gastric adenocarcinoma. Bioengineered. 2021; 12 (2):9753-9765. DOI: 10.1080/21655979.2021.1995101 - 232.
Sun H, Wu P, Zhang B, Wu X, Chen W. MCM3AP-AS1 promotes cisplatin resistance in gastric cancer cells via the miR-138/FOXC1 axis. Oncology Letters. 2021; 21 (3):1. DOI: 10.3892/ol.2021.12472 - 233.
Wang J, Wu J, Wang L, Min X, Chen Z. The LINC00152/miR-138 axis facilitates gastric cancer progression by mediating SIRT2. Journal of Oncology. 2021; 2021 :1173869. DOI: 10.1155/2021/1173869 - 234.
Xie Y, Rong L, He M, Jiang Y, Li H, Mai L, et al. LncRNA SNHG3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-139-5p/MYB axis. Aging (Albany, NY). 2021; 13 (23):25138-25152. DOI: 10.18632/aging.203732 - 235.
Yang Y, Gao M, Li Y, Li M, Ma Q. LncRNA CTBP1-AS2 facilitates gastric cancer progression via regulating the miR-139-3p/MMP11 axis. Oncotargets and Therapy. 2020; 13 :11537-11547. DOI: 10.2147/OTT.S264394 - 236.
Sun K, Hu P, Xu F. LINC00152/miR-139-5p regulates gastric cancer cell aerobic glycolysis by targeting PRKA. Biomedicine & Pharmacotherapy. 2018; 97 :1296-1302. DOI: 10.1016/j.biopha.2017.11.015 - 237.
Li Z, Cheng Y, Fu K, Lin Q , Zhao T, Tang W, et al. Circ-PTPDC1 promotes the progression of gastric cancer through sponging Mir-139-3p by regulating ELK1 and functions as a prognostic biomarker. International Journal of Biological Sciences. 2021; 17 (15):4285-4304. DOI: 10.7150/ijbs.62732 - 238.
Xia G, Wang A, Li L. Hsa_circ_0000218/hsa-miR-139-3p/SOX4 regulatory feedback circuit influences the proliferation and apoptosis of gastric cancer cells. Cytotechnology. 2022; 74 (1):89-98. DOI: 10.1007/s10616-021-00509-9 - 239.
Yang F, Peng ZX, Ji WD, Yu JD, Qian C, Liu JD, et al. LncRNA CCAT1 upregulates ATG5 to enhance autophagy and promote gastric cancer development by absorbing miR-140-3p. Digestive Diseases and Sciences. 2021; 6 :1-7. DOI: 10.1007/s10620-021-07187-9 - 240.
Sun Y, Han C. Long non-coding RNA TMPO-AS1 promotes cell migration and invasion by sponging miR-140-5p and inducing SOX4-mediated EMT in gastric cancer. Cancer Management and Research. 2020; 12 :1261-1268. DOI: 10.2147/CMAR.S235898 - 241.
Guo W, Huang J, Lei P, Guo L, Li X. LncRNA SNHG1 promoted HGC-27 cell growth and migration via the miR-140/ADAM10 axis. International Journal of Biological Macromolecules. 2019; 122 :817-823. DOI: 10.1016/j.ijbiomac.2018.10.214 - 242.
Guo H, Yang S, Li S, Yan M, Li L, Zhang H. LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer. Biomedicine & Pharmacotherapy. 2018; 102 :749-757. DOI: 10.1016/j.biopha.2018.03.024 - 243.
Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, Fushida S, et al. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene. 2012; 31 (35):3949-3960. DOI: 10.1038/onc.2011.558 - 244.
Wang Q , He Y, Kan W, Li F, Ji X, Wu X, et al. microRNA-32-5p targets KLF2 to promote gastric cancer by activating PI3K/AKT signaling pathway. American Journal of Translational Research. 2019; 11 (8):4895-4908 - 245.
Peng Q , Shen Y, Lin K, Zou L, Shen Y, Zhu Y. Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. Journal of Translational Medicine. 2018; 16 (1):127. DOI: 10.1186/s12967-018-1510-y